nature medicine l e t t e r S Ribosomal protein haploinsufficiency occurs in diverse human diseases including Diamond-Blackfan anemia (DBA) 1,2 , congenital asplenia 3 and T cell leukemia 4 . Yet, how mutations in genes encoding ubiquitously expressed proteins such as these result in cell-type-and tissue-specific defects remains unknown 5 . Here, we identify mutations in GATA1, encoding the critical hematopoietic transcription factor GATA-binding protein-1, that reduce levels of full-length GATA1 protein and cause DBA in rare instances. We show that ribosomal protein haploinsufficiency, the more common cause of DBA, can lead to decreased GATA1 mRNA translation, possibly resulting from a higher threshold for initiation of translation of this mRNA in comparison with other mRNAs. In primary hematopoietic cells from patients with mutations in RPS19, encoding ribosomal protein S19, the amplitude of a transcriptional signature of GATA1 target genes was globally and specifically reduced, indicating that the activity, but not the mRNA level, of GATA1 is decreased in patients with DBA associated with mutations affecting ribosomal proteins. Moreover, the defective hematopoiesis observed in patients with DBA associated with ribosomal protein haploinsufficiency could be partially overcome by increasing GATA1 protein levels. Our results provide a paradigm by which selective defects in translation due to mutations affecting ubiquitous ribosomal proteins can result in human disease.
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Diamond-Blackfan anemia (DBA, OMIM 105650) is characterized by a specific reduction in the production of red blood (erythroid) cells and their precursors without defects in other hematopoietic lineages 2, 6 . In more than 50% of cases, DBA is caused by heterozygous loss-of-function mutations (haploinsufficiency) in 1 of 11 genes encoding ribosomal proteins 1 . Moreover, recent studies have shown that haploinsufficiency of ribosomal proteins can contribute to other cell-type-specific diseases in humans, including congenital asplenia and T cell lymphocytic leukemia 3, 4 . How mutations that halve the quantity of ubiquitously expressed ribosomal proteins result in such specific human disorders remains unknown. Numerous theories have been proposed for the pathogenesis of these diseases 7 . However, these models do not explain the cell-type specificity of DBA and other ribosomal disorders. The experimental evidence to support such pathogenic models for DBA is often contradictory 8 . Animal models of DBA do not faithfully mimic the disease, and the involvement of different molecular pathways in the hematopoietic defects observed is variable 9, 10 .
We reasoned that identifying genetic causes for the remaining 50% of DBA cases might provide insight into the pathogenesis of this disorder. We recently identified mutations in the GATA1 gene using whole-exome sequencing 11 , the first nonribosomal gene to our knowledge to be identified in DBA. GATA1 encodes a key hematopoietic transcription factor essential for the specification of erythroid cells, as well as megakaryocytes and eosinophils, from early hematopoietic stem and progenitor cells 11, 12 . In humans, GATA1 mRNA is alternatively spliced to produce two forms of the protein: a long (or full-length) form derived from inclusion of the second exon and a short form without this exon, which therefore lacks the N-terminal 83 amino acids 11, 13 . The GATA1 mutations that we previously identified occur in the splice donor site of exon 2 and affect splicing by impairing the production of the mRNA encoding the full-length form.
It remained unclear whether the pathogenic mechanisms of these GATA1 mutations are similar to those of ribosomal protein haploinsufficiency or whether GATA1 mutations represent a distinct subset of DBA 7 . In an attempt to address this question, we undertook a systematic screening for new GATA1 mutations in over 200 additional patients with DBA. We identified a highly informative mutation in a male patient who had received a clinical diagnosis of DBA ( Fig. 1,  Supplementary Fig. 1 and Supplementary Table 1 ). This mutation changed the first translation initiation codon in GATA1, ATG, to an ACG codon ( Fig. 1a) . Consistent with X-linked inheritance, the patient's asymptomatic mother was a carrier for this mutation (Fig. 1a) . When expressed in human 293T cells, wild-type GATA1 cDNA predominantly produced the full-length form of the protein ( Fig. 1c) . In contrast, the ACG mutant cDNA predominantly produced the short form of GATA1 lacking the first 83 amino acids. In addition, this mutant cDNA produced a low level of full-length GATA1 ( Fig. 1c and Supplementary Fig. 2) , consistent with the observation that mammalian ribosomes are capable of initiating translation at specific non-AUG codons, including ACG 14 . We ruled out the possibility that the residual full-length GATA1 production resulted from contamination through the use of independent clones and by sequencing ( Supplementary Fig. 3 ). These expression analyses indicate that DBA can be caused by distinct mutations that reduce, but do not entirely abolish, production of full-length GATA1. To gain further insight into the physiological relevance of full-length GATA1 activity, we examined expression of GATA1 during human erythropoiesis and observed that expression of the full-length protein appears to be specifically upregulated in the course of erythroid differentiation (Fig. 1d) .
These results, obtained from study of the GATA1 initiator codon mutation and from our studies of human erythropoiesis, suggest that the level of GATA1 full-length protein expression is critical for the promotion of normal erythropoiesis. We reasoned that the more commonly observed mutations in ribosomal protein genes in DBA might result in anemia by reducing production of the full-length GATA1 protein, thus connecting these two seemingly disparate sets of molecular lesions. To test this hypothesis, we focused initially on the ribosomal protein gene RPS19, which is mutated in approximately 25% of DBA cases 1,2 . We used a primary human erythroid culture system to study haploinsufficiency of RPS19 using shRNA-mediated knockdown ( Fig. 2a) [15] [16] [17] . Reduced levels of RPS19 protein expression were associated with reduced GATA1 protein expression (of both the long and short forms) ( Fig. 2a) . Although this primary cell system contains mostly erythroid lineage cells, there is the possibility that cells can differentiate into nonerythroid cell types, or that differentiation within the erythroid lineage is impaired, which could confound this analysis 16 . We therefore turned to the clonal human erythroid K562 cell line to examine whether we could observe similar phenomena in a more homogenous cell population. Upon knockdown of RPS19, we observed reduced GATA1 protein levels ( Fig. 2b ) without significant effects on the levels of major cellular proteins, as assessed by Coomassie blue staining of cell lysates (Fig. 2c) . The levels of other erythroid-important proteins, including transferrin receptor, erythropoietin receptor (EPOR), Janus kinase-2, signal transducer and activator of transcription-5A (STAT5A) and T cell acute lymphocytic leukemia-1 (TAL1), were also unchanged by RPS19 knockdown (Supplementary Fig. 4a ). We observed reduced protein levels of both RPS19 and GATA1 within 4 d of infection with shRNA-encoding virus, before major effects on cell growth occurred ( Supplementary Fig. 4) . Notably, GATA1 mRNA levels were not affected ( Fig. 2d) , consistent with the notion that an effect on protein translation accounts for the decreased levels of GATA1 protein.
To directly assess whether the decrease in GATA1 protein levels is due to an effect on translation, we performed polysome profiling and fractionation ( Fig. 2e) . This approach allows for assessment of mRNA abundance in actively translating ribosomes that are present in multiple copies on a single mRNA species, thereby forming polysomes indicative of productive translation initiation 18, 19 . Whereas the level of GATA1 mRNA associated with monosomes was similar or higher in RPS19-knockdown cells as compared with controls ( Supplementary Fig. 5 ), there was a two-to threefold reduction in GATA1 mRNA abundance in polysomes ( Fig. 2f) . In contrast, all other erythroid-important mRNAs tested showed a different pattern, with similar or increased abundance in larger polysomes following RPS19 knockdown ( Fig. 2g) . As an alternative approach to demonstrate a selective reduction in GATA1 translation, we labeled cells with the methionine analog l-azidohomoalanine 20 . When we performed chemical detection of l-azidohomoalanine on immunoprecipitated GATA1, we found a reduced level of newly translated GATA1 in cells with reduced RPS19 levels ( Supplementary Fig. 6 ). Global translation was decreased to ~40% of that in controls ( Supplementary  Fig. 7) , consistent with the slowing of cell growth observed upon RPS19 knockdown and the known global reduction of translation (48-75%) in patients with DBA 21, 22 .
To gain insight into the mechanism by which ribosomal protein haploinsufficiency results in the observed selective defect in translation, we examined the effect of reducing the expression of other DBA-associated ribosomal proteins. When we used shRNA constructs to reduce expression of RPL11, RPL5 or RPS24, which are collectively mutated in ~15% of DBA cases 1 , we consistently noted decreased protein levels of GATA1 ( Fig. 3a-c) . The degree of reduction in GATA1 protein levels corresponded well with the extent of knockdown observed for the various ribosomal proteins (Fig. 3a-c and Supplementary Fig. 8 ). Highlighting the selectivity of this effect, the protein levels of other regulators of erythropoiesis such as EPOR, TAL1, transferrin receptor (CD71) and STAT5A showed no change after ribosomal protein knockdown ( Fig. 3a-c) , consistent with the results seen with RPS19 knockdown.
The similar defect in GATA1 translation resulting from reduction of ribosomal proteins from either the 40S or 60S subunit of the ribosome suggests that an impairment of translation initiation may underlie this observation, which is consistent with the concept that the availability of free ribosomes is the rate-limiting step in translation initiation 23 . Eukaryotic translation initiation factors (eIFs) play a critical role in translation initiation. This process begins as eIF4E initially interacts with the 5′ terminal cap of mRNAs and then binds eIF4G, which in
Time of differentiation (d) Figure 1 A GATA1 mutation in DBA impairs full-length GATA1 protein production. (a) Sanger sequencing in the region of the first initiator codon from exon 2 of GATA1 in a male patient with DBA, the patient's mother and a healthy control. (b) Bone marrow aspirate (top, 100× objective magnification, scale bar 10 µM) stained with Wright-Giemsa and a section from a bone marrow biopsy (bottom, 50× objective magnification, scale bar 30 µm) stained with H&E from the patient with DBA. (c) Western blot for detection of full-length (GATA1 FL) and short (GATA1s) forms (arrowheads) of GATA1 in extracts of 293T cells transfected with no vector (Empty), HMD lentiviral vector (HMD only), HMD-GATA1 wild-type vector (GATA1) or the HMD-GATA1 mutant vector (GATA1 T>C mut). GAPDH was used as a loading control, (d) Western blots for detection of GATA1 FL and GATA1s in extracts from primary differentiating erythroid cells in culture. β-actin was used as a loading control.
npg l e t t e r S turn recruits multiple factors, including eIF4A and eIF3, and allows the ribosome to overcome restrictive motifs in the 5′ untranslated region (5′ UTR) to scan for the appropriate translation initiation AUG codon 24 . We therefore used a selective inhibitor of the eIF4E-eIF4G interaction (termed 4EGI-1) to examine whether inhibition of this interaction would also selectively affect GATA1 translation [25] [26] [27] . Notably, treatment of K562 cells with 4EGI-1 for 48 h led to a marked decrease in GATA1 protein, whereas other proteins tested were largely unaffected ( Fig. 3d) . This result shows that GATA1 mRNA has a more stringent requirement for eIF-dependent translation initiation compared to a number of other transcripts. Knockdown of the expression of RPS19, RPL11, RPL5 or GATA1 in primary CD34 + cell cultures resulted in a decreased ratio of erythroid to nonerythroid cells (as assessed using the erythroid marker CD235a, also known as glycophorin A) ( Supplementary Figs. 9 and 10) , a phenotype characteristic of DBA 15, 16 . Treatment of the primary cell cultures with 4EGI-1 caused a similar and dose-dependent decrease in the relative amount of erythroid cells ( Fig. 3e and Supplementary Fig. 11 ). Notably, this decrease was associated with a reduction in GATA1 protein levels but not with changes in the levels of other tested proteins (Fig. 3f) . The decreased erythropoiesis observed with 4EGI-1 treatment could largely be rescued by overexpression of GATA1 ( Supplementary Fig. 12 ), suggesting that GATA1 is a critical downstream target when the eIF4E-eIF4G interaction is inhibited. Collectively, these results show that the reduction in GATA1 translation observed with reduced ribosomal protein levels probably reflects a broad sensitivity of GATA1 mRNA to impairment of translation initiation. Cells can physiologically regulate gene expression through variation of mRNA translation initiation potential, as different mRNAs can have variable barriers to translation 23, 24 . A number of studies have demonstrated that transcripts with highly structured 5′ UTRs are more poorly translated and have a need for increased initiation potential by the cell 23, 24, 28, 29 . As the 5′ end of human GATA1 mRNA has never been fully characterized, we performed rapid amplification of the 5′ cDNA ends (5′ RACE) of human GATA1 transcripts from both primary erythroid and K562 cells. This analysis revealed a previously unreported 5′ end of GATA1 mRNA that we found on the majority of clones encoding either the short or the long mRNA isoform ( Supplementary Fig. 13a,b) . The 5′ end of human GATA1 mRNA was predicted to be highly structured ( Supplementary Fig. 13c ), and thus translation may be more readily impaired in settings where the translation initiation potential is reduced, such as with ribosomal protein haploinsufficiency 23, 29, 30 . In support of this notion, we found using a reporter assay that the GATA1 5′ UTR restricted translation to a greater extent than did other 5′ UTRs of similar length (Supplementary Fig. 13d ). Additionally, other transcripts with highly structured 5′ UTRs showed reduced association with larger polysomes (Supplementary Fig. 14) , whereas the association of transcripts with unstructured 5′ UTRs with larger polysomes was not affected or was upregulated ( Fig. 2g) . Therefore, downregulation of translation of GATA1 mRNA-one of a select group of transcripts with a highly structured 5′ UTR-may act as an Achilles' heel during hematopoietic development to impair erythropoiesis specifically in the context of DBA, consistent with our finding that rare mutations in the GATA1 gene itself are capable of causing DBA. It is possible that other undefined regulatory or structural motifs in the 5′ UTR of GATA1 mRNA could explain the observed effect on translation in the setting of reduced ribosomal protein levels, but we have been npg unable to identify any characteristic motifs in this sequence. Mouse Gata1 mRNA has a much shorter and less structured 5′ UTR than that of humans 31 , which may explain the failure of ribosomal protein haploinsufficiency to downregulate translation of this gene and cause major impairments of erythropoiesis in mouse models 8 .
To test whether our findings are of relevance in patients with DBA with mutations in genes encoding ribosomal proteins, we sought to assess GATA1 in erythroid cells from these patients. Given the difficulty of obtaining a sufficient number of stage-matched erythroid cells from patients with DBA to enable examination of GATA1 protein levels, we used RNA expression data to determine whether there was an alteration in the expression of GATA1 target genes. We performed global gene expression profiling on sorted erythroid progenitors (CD34 + CD71 high CD45RA − bone marrow mononuclear cells) from three patients with DBA with known RPS19 mutations (Online Methods) and six control subjects. This cell surface phenotype is known to selectively enrich for early erythroid progenitors (erythroid burst-forming and erythroid colony-forming units, or BFU-Es and CFU-Es, respectively); similar colony numbers are obtained from healthy individuals and patients with DBA 32, 33 . After normalization of the gene expression data, we examined both global gene expression and expression of a curated set of GATA1 target genes (Supplementary Fig. 15 ). The global gene expression profiles showed a high degree of correlation between DBA and control erythroid progenitors (R 2 = 0.990; Fig. 4a ), indicating that we obtained comparable populations of cells from the patients and control subjects. We then applied the gene set enrichment analysis (GSEA) algorithm to assess the expression of GATA1 target genes 34 . Consistent with our hypothesis, we noted significant global downregulation of GATA1 target genes in erythroid progenitors from patients with DBA compared with controls ( Fig. 4c,d, Supplementary  Fig. 15 and Supplementary Tables 2-4 ). Of over 600 target gene sets for other transcription factors (based on the presence of transcription factor binding sites; Online Methods), none demonstrated such a marked and global downregulation, highlighting the selectivity of the effect on GATA1 activity. Notably, the expression of target genes for several other erythroid-important transcription factors and for the tumor suppressor p53 showed no significant changes ( Supplementary  Fig. 16 and Supplementary Table 5 ). GATA1 mRNA levels were comparable between DBA and control samples (Fig. 4b) , providing support for the idea that altered GATA1 activity in DBA cells is mediated at the translational rather than transcriptional level. These results demonstrate that GATA1 activity is decreased in primary samples from patients with DBA with RPS19 mutations, consistent with the idea that GATA1 dysfunction underlies the erythroid differentiation defect in DBA.
We next examined whether reduced GATA1 levels are sufficient to impair erythropoiesis. When either ribosomal proteins or GATA1 were targeted with shRNAs, we consistently observed increased apoptosis, decreased cell numbers and decreased erythroid differentiation of primary hematopoietic cells (Supplementary Figs. 4, 9 and 10) . These findings are consistent with observations made in patients with DBA with mutations in the genes encoding these ribosomal proteins or GATA1 11 . We modified the GATA1 cDNA to contain an optimized 5′ UTR lacking known structural barriers to translation, such that it should be effectively translated 24 . Infection with lentivirus harboring this modified GATA1 cDNA rescued the increased apoptosis of erythroid cells with RPS19 knockdown, whereas the mutant GATA1 cDNA that predominantly produces the short form of the protein showed only partial rescue ( Supplementary Fig. 17a,b) . To assess whether GATA1 could rescue the defect in erythroid differentiation observed in primary hematopoietic cells with reduced ribosomal protein levels, we concomitantly transduced primary cultured CD34 + cells with shRNAs targeting RPL11 or RPL5 and with the modified GATA1 cDNA or appropriate controls. Introduction of GATA1 into these cells improved erythropoiesis (Supplementary Fig. 17c) to an extent comparable to that observed with introduction of the deficient ribosomal protein gene itself 35 , whereas the mutant version of GATA1 had a lower level of rescue activity. Notably, introduction of GATA1 lentivirus into primary bone marrow mononuclear cells from patients with DBA resulted in a two-to fourfold increase in the ratio of CD235a + erythroid to CD235a − nonerythroid cells (Fig. 4e,f) . Not only was the frequency of erythroid cells increased, but there was also an improvement in erythroid differentiation, as indicated by smaller cell size (a reduced cell size characterizes more mature erythroid cells), mature erythroid cell morphology and increased expression of genes critical for terminal erythroid maturation (Fig. 4g-i and Supplementary  Fig. 18 ) 36 . These findings show that GATA1, although likely not the only target of dysregulated protein translation in DBA, is a key factor in mediating the erythroid-specific defect observed in this condition. npg l e t t e r S Given the limitations in comparing erythroid differentiation in samples from patients with DBA, which show delayed and impaired maturation, with erythroid differentiation in cells from normal individuals 37 , the extent of this rescue is difficult to quantitatively assess and is likely to be partial. Nonetheless, these results suggest that modulation of GATA1 protein levels in the context of ribosomal protein haploinsufficiency can improve erythropoiesis, with implications for potential therapeutic approaches to ameliorate DBA and related forms of anemia, such as that observed in 5q-myelodysplastic syndrome 35 . Our finding of impaired translation of GATA1 mRNAs by ribosomes in DBA adds to an increasing appreciation for the role of translational control in mediating cell-type-specific gene expression 5 . We showed that mutations in the GATA1 gene itself can cause DBA by reducing full-length protein levels, and that the more common mutations in genes encoding ribosomal proteins result in impaired erythropoiesis through, at least in part, the same mechanism of decreased GATA1 protein production (Supplementary Fig. 19 ). Although prior work has implicated p53 in mediating some of the defects observed in DBA 7, 15 and has shown that GATA1 regulates the p53 pathway 38 , the defects we observed in K562 cells upon GATA1 or ribosomal protein knockdown occurred in the absence of p53 (ref. 39) . Thus, the cell-type specific nature of the DBA phenotype is probably mediated by multiple pathways, including the p53 pathway, that lie downstream of GATA1. Indeed, we observed that p53 expression is upregulated upon reduction of RPS19 or GATA1 levels in primary hematopoietic cells, suggesting that these factors act through a common pathway (Supplementary Fig. 20) .
More generally, our findings suggest that mRNAs that are inefficiently translated by the ribosome experience a further reduction in protein translation under conditions of limited ribosome abundance (or with other impairments in translation initiation), such that synthesis of their encoded proteins would be selectively impaired 23, 40 . Alterations in protein translation have been implicated in diverse human diseases including autism, cancer and other blood disorders 26, 27 . Our finding of selectively impaired protein translation resulting from ribosomal protein haploinsufficiency provides a paradigm for understanding the cell-type-specific defects observed in DBA and conditions such as congenital asplenia 2,3 and childhood leukemia 4 . In addition, the deeper understanding of DBA pathogenesis that is presented here suggests potential therapeutic avenues that would involve targeting of GATA1 protein production through either gene therapy or small-molecule approaches for amelioration of the anemia observed in this disease. npg
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Cell culture. 293T cells (ATCC) were maintained in DMEM with 10% FBS (FBS), 2 mM l-glutamine and 1% penicillin-streptomycin (P/S). K562 cells (ATCC) were maintained at a density between 0.1 × 10 6 and 1 × 10 6 cells per milliliter in RPMI 1640 medium supplemented with 10% FBS, 2 mM l-glutamine and 1% P/S. Culture of primary human cells is described below. Cells were incubated at 37 °C with 5% CO 2 . Where indicated, cultures were supplemented with 10-100 µM 4EGI-1 (sc-202597, Santa Cruz Biotechnology) or DMSO.
Culture of human adult peripheral blood-mobilized CD34 + progenitors was performed using a two-stage culture method, as described previously 17, 41 . CD34 + cells were obtained from magnetically sorted mononuclear samples of G-CSF-mobilized peripheral blood from donors and were frozen after isolation. Cells were obtained from the Fred Hutchinson Cancer Research Center, Seattle, USA. Cells were thawed and washed into PBS with 1% FBS, pelleted and then seeded in StemSpan SFEM medium (StemCell Technologies, Inc.) with 1× CC100 cytokine mix (Stem Cell Technologies, Inc.) and 1% P/S. Cells were maintained in this expansion medium at a density between 0.1 × 10 6 and 1 × 10 6 cells per milliliter, with medium changes every other day as necessary. Cells were kept in expansion medium for a total of 5 d. After this expansion phase, the cells were reseeded into StemSpan SFEM medium with 1% P/S, 20 ng/mL SCF (PeproTech, Inc.), 1 U/mL Epo (Amgen), 5 ng/mL IL-3 (PeproTech, Inc.), 2 µM dexamethasone (Sigma-Aldrich) and 1 mM β-estradiol (Sigma-Aldrich). Cells were maintained in differentiation medium, with medium changes every other or every third day as needed. Cells were maintained at a density between 0.1 × 10 6 and 1 × 10 6 cells per milliliter.
Bone marrow mononuclear cells from patients with DBA and healthy controls were isolated from human bone marrow aspirates using Ficoll-Paque Plus (17-1440-02, GE Healthcare) density gradient centrifugation. Mononuclear cells were cultured in IMDM with 3% human type AB plasma, 2% human AB serum, 1% P/S, 3 U/ml heparin, 200 µg/ml Holo-Transferrin (Sigma-Aldrich), 10 µg/ml insulin, 10 ng/ml SCF (PeproTech, Inc.), 1 ng/ml IL-3 (PeproTech, Inc.), 2 µM dexamethasone (Sigma-Aldrich) and 3 U/ml Epo (Amgen), similarly to recently described protocols for culturing human erythroid cells 36 . Cells were cultured for 1-2 d before infection as described below and analyzed 4-5 d after infection.
Bone marrow mononuclear cells from patients with DBA or healthy donors were collected after appropriate informed consent was obtained. Patient 1 was male and was 6 months old at the time of bone marrow collection. The patient had been noted to have fussiness and pallor at 4 months of age, and a complete blood count performed at that time showed a hemoglobin level of 4.3 g/dL. The patient remained on monthly transfusions to avoid symptomatic anemia. The patient had no physical anomalies. The erythrocyte adenosine deaminase level was elevated at 1.83 IU per gram of hemoglobin. All 11 known ribosomal protein genes, as well as GATA1, were sequenced in this patient, and no definitive pathogenic mutations were found. Patients 2 and 3 were both male and were 34 and 27 years old, respectively, at the time of bone marrow collection. These patients both had a macrocytic anemia that was diagnosed in infancy. Both individuals had required intermittent transfusions, but details of their medical history were limited, as only select records were available for review. Both patient 2 and patient 3 were dependent on steroid therapy to prevent the need for transfusions. Neither individual had any physical anomalies, and erythrocyte adenosine deaminase levels were elevated at 0.99 and 1.92 IU per gram of hemoglobin (normal range 0.33-0.96 IU per gram of hemoglobin), respectively. Patients 2 and 3 had the Lentiviral vectors and infection. The shRNA constructs targeting human RPS19 (sh913 and sh916, RefSeqID NM_001022), human GATA1 (sh19-23, RefSeq ID NM_002049), human RPS24 (sh1-2, RefSeq ID NM_001026), human RPL5 (sh1-5 RefSeq ID NM_000969) and human RPL11 (sh1-5 RefSeq ID NM_000975) were obtained from the Mission shRNA collection (Sigma-Aldrich). The constructs were in the pLKO.1-puro lentiviral vector. The sequences of the shRNAs used in this study are listed in Supplementary Table 6 .
As controls, the lentiviral vectors pLKO-GFP and pLKO.1s (the empty pLKO.1 vector with a 1.2-kb stuffer element) were used (The RNAi Consortium of the Broad Institute of MIT and Harvard). For rescue experiments, erythroid cells were cotransduced with shRNAs targeting ribosomal proteins with either the HMD control, HMD-GATA1 or HMD-GATA1 mutant, which contain the respective cDNAs. The HMD-GATA1 construct was made by subcloning the GATA1 cDNA into the HMD lentiviral vector using the EcoRI and XhoI restriction sites in this vector. The HMD-GATA1 T>C mutant construct was made by performing site-directed mutagenesis of the original HMD-GATA1 construct using the QuikChange II site-directed mutagenesis kit (Agilent). Double-transduced cells were identified by puromycin selection and GFP expression driven by an IRES-GFP in the HMD vector.
For production of lentiviruses, 293T cells were transfected with the appropriate viral packaging and genomic vectors (pVSV-G and pDelta8.9) using FuGene 6 reagent (Promega) according to the manufacturer's protocol. The medium was changed the day after transfection to RPMI 1640 or StemSpan SFEM medium. After 24 h, this medium was collected and filtered using an 0.45-µm filter immediately before infection of primary hematopoietic or K562 cells. The cells were mixed with viral supernatant in the presence of 8 µg/ml polybrene (Millipore) in a 6-well plate at a density of 250,000-500,000 cells per well. The cells were spun at 2,000 r.p.m. for 90 min at 22 °C and left in viral supernatant overnight. The medium was replaced the morning after infection. Selection of infected cells was started 24 h after infection with 1 µg/ml or 2 µg/ml puromycin for primary hematopoietic cells and K562 cells, respectively. The infection efficiency for pLKO-GFP-infected cells was assessed by measuring the frequency of GFP + cells by flow cytometry 48 h post infection. Typically, the frequency of GFP + cells was between 30-60% and >95% for primary hematopoietic cells and K562 cells, respectively.
Quantitative RT-PCR. Isolation of RNA was performed using the miRNeasy Mini Kit (Qiagen). An on-column DNase (Qiagen) digestion was performed according to the manufacturer's instructions. RNA was quantified by a NanoDrop spectrophotometer (Thermo Scientific). Reverse transcription was carried out using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using the ABI 7900 Machine Real-Time PCR system and SYBR green PCR Master Mix (Applied Biosystems). Quantification was performed using the ∆∆C T method. Normalization was performed using β-actin mRNA as a standard, unless otherwise indicated. The primers used for quantitative RT-PCR are listed in Supplementary Table 7. 5′ RACE. 5′ RACE was conducted using total RNA from K562 cells and in vitro cultured primary erythroid cells using the FirstChoice RLM-RACE Kit (AM1700, Life Technologies) according to the manufacturer's instructions. RACE PCR products were subcloned using the TOPO TA cloning kit (450641, Invitrogen) followed by Sanger sequencing. The primers used for 5′ RACE are listed in Supplementary Table 7 .
Western blotting. Cells were harvested at indicated time points, washed twice in PBS, resuspended in RIPA lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 1 mM DTT) supplemented with 1× Complete Protease Inhibitor Cocktail (Roche) and incubated for 30 min on ice. After centrifugation at 14,000 r.p.m. for 10 min at 4 °C to remove cellular debris, the remaining supernatant was transferred to a new tube, supplemented with sample buffer and incubated for 10 min at 70 °C. Equal amounts of proteins were separated by SDS gel electrophoresis using the NuPAGE Bis-Tris gel system (Invitrogen) and MOPS running buffer. Subsequently, proteins were transferred onto a PVDF membrane using NuPAGE transfer buffer (Invitrogen). Membranes were blocked with 3% BSA-PBST for 1 h and probed with GATA1 goat polyclonal antibody (M-20, sc-1234, Santa Cruz Biotechnology) at a 1:500 dilution, RPS19 mouse monoclonal antibody (WW-4, sc-100836, Santa Cruz Biotechnology) at a 1:500 dilution, RPL5 goat polyclonal (D-20, sc-103865, Santa Cruz Biotechnology) at a 1:500 dilution, RPL11 goat polyclonal (N-17, sc-25931, Santa Cruz npg
